Evaluation of the Clinical Effects and Frequency of MEFV Gene Mutation in Patients with Inflammatory Bowel Disease

Table 4

Effect of MEFV mutations on clinical variables.

	Variables		Mutation (+)/	Mutation (-)/	value
UC,	Surgical requirement		3/8	2/47	0.018
	Biologic agent requirement		1/8	9/47	>0.999
	Immunomodulator requirement		3/8	23/47	0.708
	Steroid usage		3/8	27/47	o.446
	Recurrent disease		3/8	16/47	>0.999
	UC localization	Extensive colitis	5/8	30/47	>0.999
		Left colitis (+proctitis)	3/8	17/47
	Extraintestinal manifestations		7/8	41/47	>0.999
	Age of onset of the disease ()				0.558
CD,	Surgical requirement		5/12	9/33	0.470
	Biologic agent requirement		6/12	14/33	0.651
	Immunomodulator requirement		11/12	26/33	0.419
	Steroid usage		10/12	24/33	0.699
	Recurrent disease		9/12	17/33	0.158
	CD localization	İleal	5/12	10/33	0.496
		Colonic and ileocolonic	7/12	23/33
	CD behavior	Fibrotic	3/12	5/33	0.661
		Others	9/12	28/33
		Fistulizing	3/12	11/33	0.725
		Others	9/12	22/33
	Perianal disease		3/12	9/33	>0.999
	Extraintestinal manifestations		9/12	27/33	0.682
	Age of onset of the disease ()				0.253

CD: Crohn’s disease; UC: ulcerative colitis; MEFV: Mediterranean Fever gene.